Is N-acetyl-3,4-dihydroxybutyl cysteine a urinary metabolite of 1,3-butadiene?

The claim is well supported. N-acetyl-3,4-dihydroxybutyl cysteine—when referring to N-acetyl-S-(3,4-dihydroxybutyl)-L-cysteine (DHBMA/34HBMA)—is a urinary mercapturic acid produced during metabolism of 1,3-butadiene. More broadly, mercapturates are biologically grounded markers of glutathione-dependent handling and urinary elimination of electrophiles or their reactive metabolites.

Metabolic and mechanistic evidence

• 1,3-Butadiene undergoes CYP-mediated bioactivation to 3,4-epoxy-1-butene (butadiene monoepoxide), a reactive electrophilic intermediate.
• Hydrolysis of this epoxide produces butadiene-diol; glutathione-dependent metabolism then leads to DHBMA formation.
• The glutathione conjugate is processed by sequential removal of glutamate and glycine, followed by N-acetylation of the cysteine conjugate, yielding the urinary mercapturate.
• This sequence establishes DHBMA as a downstream product of butadiene metabolic processing and elimination, not simply a correlated analyte.

Human biomarker interpretation

• DHBMA is among the principal urinary butadiene mercapturates in humans. In occupational styrene–butadiene workers, urinary DHBMA, MHBMA, and THBMA were higher than in controls and correlated with airborne butadiene and hemoglobin adduct measures.
• Urinary mercapturates are generally relatively polar renal-excretion products and can indicate recent absorbed exposure and metabolic processing. Concentrations depend substantially on sampling timing, because many have short elimination half-lives.

Practical limitations

• DHBMA has appreciable, variable background urinary excretion and is not uniquely attributable to butadiene in an individual sample; it may not reliably distinguish smokers from nonsmokers. MHBMA is generally more sensitive for low-level recent butadiene exposure and more specific for smoke-related exposure.
• Mercapturate concentrations also reflect glutathione availability, conjugating/acetylating enzymes, genotype, kidney transport and clearance, hydration, and urine-dilution adjustment; they do not directly quantify toxicity, disease risk, or global “detoxification” capacity.

Bottom line

• DHBMA is an established urinary mercapturate of 1,3-butadiene, and mercapturic acids generally reflect glutathione conjugation followed by predominantly urinary elimination of electrophilic chemicals or reactive metabolites.